For reprint rights or to purchase a copy of your Daily Journal photo, email jeremy@reprintpros.com for prices or call 949-702-5390.

To buy more copies, call 866-531-1492 or email subscribe@dailyjournal.com
This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...
You must have a membership to view this page.

Entertainment & Sports

May 11, 2010

Lions Gate's Poison Pill Squashed

A court in British Columbia Friday denied Lions Gate Entertainment's effort to use a poison pill to prevent a hostile takeover by investor Carl Icahn.

By Jean-Luc Renault

Daily Journal Staff Writer

A court in British Columbia Friday denied Lions Gate Entertainment's effort to use a poison pill to prevent a hostile takeover by investor Carl Icahn. The billionaire, who already owns 18 percent of the Santa Monica-based studio that's registered in Vancouver, extended his $7-per-share offer to stockholders through Monday.

<a style="color:#123f72;"

href="m...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up



By using our website, you agree to our use of cookies in accordance with our cookie policy. You can learn more about how we use cookies by reviewing our Privacy Policy here.